• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice Q&A: Charles Remsberg

MassDevice Q&A: Charles Remsberg

July 2, 2009 By Brian Johnson

Charles Remsberg literally learned the medical device business from the ground up.

The 47-year-old’s first job in the industry was sweeping the floors in a warehouse. That’s also where he learned that it’s more important to be judged by your work than your alma mater’s pedigree.

The Long Island native’s resumé includes stints ranging from clam digger to his current role as CEO of the American division of Hocoma Inc. in Rockland. Switzerland-based Hocoma produces the Lokomat, a robotic rehabilitation system that helps people suffering from spinal cord injuries and brain trauma learn how to walk again by acting as their legs.

Remsberg talked to MassDevice about the Lokomat, how robotics will change the rehabilitation (and maybe the medical) business and why thinking Swiss has helped Hocoma avoid the pitfalls of the current economic climate despite a capital equipment purchasing drought.

MassDevice: What was your first job?

Charles Remsberg: I used to make bagels in high school and I was also a commercial fisherman. At 16 I started digging clams. Oh, and when I was 12, I had a paper route. I’m a hard worker. I’ve always worked and always been a hard worker.

MassDevice: Where are you from and how did you get into the medical device business?

CR: I’m from Long Island originally. I started my medical device career in college, working for Biodex Medical Systems between semesters and in the summer. I was 19 years old when I started, basically just sweeping the floors. I was the rookie, so I spent my days pouring acetone and working.

MassDevice: Where’d you go to school?

CR: I went to UMass-Amherst, Stonybrook College and I have an Associate’s degree from Suffolk County Community College in business and administration.

MassDevice: You don’t have a Bachelor’s degree?

CR: I only have an Associate’s degree. I think education is important, but it’s more the kind of person you are that’s important. It’s kind of ridiculous to judge people by their education.

I spent 21 years at Biodex, working my way up from the warehouse all the way to running the physical medicine and rehabilitation division. But after 21 years, I realized I wasn’t going to be doing anything else other than running the divisions. I decided that it was time for me to try something else. My neighbor at the time owned a large boat dealership on Long Island and had a dysfunctional relationship with his employees, so I went to work with him in the boat business for a year. Basically, long enough to help him out and give me a good reason to get out of Biodex and do something else.

By the end of that year, I knew didn’t want to be in boat business, so we moved to Switzerland to raise our daughter. By pure serendipity I was introduced to the founders of Hocoma by my wife’s girlfriend’s ex-boyfriend, who was the Chief Technology Officer. They were looking for a sales and marketing guy in the U.S., and when they heard I was moving to Switzerland they wanted to talk about the opportunity to run sales and marketing in Switzerland. I was their ninth employee.

I was the head of sales and marketing and the first salesperson they hired. I set up international distribution from Switzerland and it became clear that the U.S. was a very important market for the company. The CEO and board of directors asked if I’d consider moving back to the States. That was in 2006 and now I’ve been CEO of the U.S. division for three years. We went just from myself to our 10th employee.

MassDevice: Can you describe the Lokomat for a layman?

CR: The Lokomat is a robotic exo-skeleton that is strapped to a patient with a spinal cord injury, brain injury, or a stroke victim. The robotic legs assist them in walking on a treadmill.

In essence, you’re training the central nervous system. The idea is neural plasticity. We’ve all heard the parable that we only use 10 percent of our brain, but when you have neurological injury your brain’s ability to contact the limbs is diminished. So the brain tries to find a different neural pathway to get to the limb, or tries to recruit other parts of the brain to control that aspect of function. Neurological rehabilitation is not rehabbing strength; you’re trying to stimulate the central nervous system to develop the brain’s level of control over those limbs.

A good example is people who’ve had a stroke and lost control over the left side or the right side of their body. Over time, after the shock of trauma wears off, many people recover function. That’s because the body was in shock and lost that control of those limbs, but over time recovered it.

What’s different about Hocoma is the concept is motor function. If you play tennis or golf, the only way to get good is to have a high number of repetitions. They say a million repetitions are required to be successful in golf.

In therapy, it’s the same story, because the patient has lost a significant amount of function. So it takes high intensity to regain neuromuscular control, and robotics is ideal for high reps with intensity. And at the same time, it can assess the patient’s condition, provide a form of feedback.

MassDevice: Who are your customers?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Remsberg_Charles_100x100.jpg}CR: We sell to large free-standing rehabilitation hospitals like Spaulding Rehabilitation Hospital in Boston, as well as medical centers and small rehabilitation centers. We also sell to a group of people who provide exercise for people with brain injuries. That’s a cool business, because as a consumer the amount of medical care allowed is limited by insurance. With a brain injury, after the allied health portion of rehab is completed, the costs are extremely high. So those patients have a limited amount of therapy and after six weeks they’re kicked out. These people look for places they can train, so some of these small private rehab centers have opened up. They’re mostly funded as a non-profit and they usually offer a fee-for-service, sort of like a gym for people with spinal cord injuries. There’s one called Journey Forward in Canton.

MassDevice: How much does the Lokomat cost?

CR: Our price point starts at just more than $200,000 for the Lokomat and goes up as high as high as $380,000 for the pediatric version. What’s really great is the success of the technology with children. Spaulding was the first to get a pediatric version and they’ve conducted research that showed extraordinary gains in patients with cerebral palsy.

MassDevice: With hospitals cutting their capital expenditures and generally cutting costs, how do you prove the value of a large piece of equipment like the Lokomat to the finance people?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/featureArt/Lokomat_200.jpg}CR: Obviously, the short-term uptake is a lot slower than it was in 2006 or 2007. There’s a lot of facilities that want the Lokomat but have to delay until 2010-2011. At the same time, there are enough facilities that are well-run and well-positioned and which look at a downturn as a good time to differentiate from competitors. Our feeling is that year-on-year sales will increase; we’ll sell more this year than we did last year. But what’s also important is that we’re a bootstrapped company. We’re profitable and our event horizon is 10 years. The slowdown is inconvenient, but it’s not a bet-the-company scenario.

We’re not worried about overnight success. Yes, we have to sell, we have to work to get orders, but there’s not as much of a whip-saw effect as you see in some American companies that are run on the edge.

MassDevice: Does that outlook stem from Hocoma’s Swiss origins?

CR: Our management team has had the foresight to be successful. There’s no venture capitalists invested in Hocoma. We’re not interested in investors with short event horizons. Somebody who wants to get in and get out is not the right fit for us. We have private investors and we’re absolutely clear that an investment in Hocoma is an investment in the long term.

MassDevice: How does the Swiss business culture differ from American customs?

CR: No one person does anything alone. We do it as a team. It’s actually how we live. Consensus management is a Swiss concept. We have a hierarchical structure to our society. Our theory is that you disagree behind closed doors, but when we go out in public we’re unanimous. It’s not just in business, either.

MassDevice: What do you think the medical device business going to look like in 20 years?

CR: That’s the $64 billion question, isn’t it? What I tell people is that in physical medicine, robotics is the ideal medium. Robotics will play a large role in rehabilitation and physical medicine. The future is still quite dynamic and it will attract competitors, which is good because you don’t have a market without competition and we hope that we’re a leader in that field.

In a broader sense, robotics will play a large role in medicine. It’s only a matter of where that role will make itself known. Distribution on a large scale in retail services is a natural fit, but the same thing could be said about a hospital. There’s no reason robots can’t deliver food and clothes in a hospital. I’d be surprised if they weren’t used in hospitals.

MassDevice: And in medicine, can you see robots performing procedures?

CR: Maybe, it could be like “Star Wars,” I don’t know. The DaVinci system is the de facto standard for some surgical procedures. But cost is one side of the equation. In our business model, cost is part of it because instead of humans moving the person, you have a robot. One reality of the healthcare system is it’s very hard to justify therapy that involves more than one person. So with increasing precision, increasing success, increasing efficiency and in many surgical procedures, robotics blows away outcome with less investment and physician intervention.

MassDevice: With the increasing prevalence of gift bans and other regulations, will the industry ever go from a face-to-face transactions to e-commerce?

CR: Thank God, no. Not in my lifetime. I think all types of selling, whether it’s cars, newspapers, whatever, requires that you develop a recognizable level of expertise. We’re all becoming experts in our niche. The salespeople become experts in their niches. The biggest falsehood is the saying, “I can sell anything.”

Successful companies will develop expertise. The conveyance of information is still human-to-human, whether personally or through video conferences, and the conveyance of information has to be made through the expert. We’re training people to become experts. That’s my personal niche, I’m an expert in physical medicine. I didn’t jump around from industry to industry. I developed 25 years of providing a high level of consultative information. People trust my information, trust my reputation.

If you look at the people who followed the curve from dot-com, real estate, to mortgages, I’m sure they were great salespeople, but the problem is they aren’t experts. You can be the best closer in the world, it doesn’t matter. If you don’t understand our material, you won’t be successful.

MassDevice: Speaking of the gift ban, what’s your take on its potential impact on your company and the industry in general?

CR: We never give gifts, so it’s not anything that affects us as a company. Personally, I’m opposed to buying lunch for a presentation. The doctors speak to us because the information is valuable. One of the great things about working for an innovative company is that when you call somebody, they take the call. You don’t have to try anything crazy to get in the door. You just have be yourself.

MassDevice: What other rules or regulations have you most concerned?

CR: None. I feel that we’re a part of the solution, not part of the problem.

Filed Under: Business/Financial News Tagged With: MassDevice Q&A, Rehabilitation Equipment

In case you missed it

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS